Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 2211-2214, 2007. First published September 27, 2007; 10.1373/clinchem.2007.093781
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 093781.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.093781v1
53/12/2211    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Laurie, A. D.
Right arrow Articles by George, P. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laurie, A. D.
Right arrow Articles by George, P. M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Hemostasis and Thrombosis
(Clinical Chemistry. 2007;53:2211-2214.)
© 2007 American Association for Clinical Chemistry, Inc.

Technical Briefs

Detection of Factor VIII Gene Mutations by High-Resolution Melting Analysis

Andrew D. Lauriea, Mark P. Smith and Peter M. George

(Department of Molecular Pathology, Canterbury Health Laboratories, Christchurch, New Zealand;

aaddress correspondence to this author at: P.O. Box 151, Christchurch, New Zealand; fax 64-3-3640545, e-mail andrew.laurie{at}cdhb.govt.nz)


Abstract

Background: Single base-pair substitution mutations in the gene for coagulation factor VIII, procoagulant component (hemophilia A) (F8) account for approximately 50% of severe cases of hemophilia A (HA), and almost all moderate or mild cases. Because F8 is a large gene, mutation screening using denaturing HPLC or DNA sequencing is time-consuming and expensive.

Methods: We evaluated high-resolution melting analysis as an option for screening for F8 gene mutations. The melting curves of amplicons heterozygous for known F8 gene mutations were compared with melting curves of the corresponding normal amplicons to assess whether melting analysis could detect these variants. We examined 2 platforms, the Roche LightCycler 480 (LC480) and the Idaho Technology LightScanner.

Results: On both instruments, 18 (90%) of the 20 F8 gene variants we examined were resolved by melting analysis. For the other 2 mutations, the melting curves of the heterozygous amplicons were similar to the corresponding normal amplicons, suggesting these variants may not be detected by this approach in a mutation-scanning screen.

Conclusion: High-resolution melting analysis is an appealing technology for F8 gene screening. It is rapid and quickly identifies mutations in the majority of HA patients; samples in which no mutation is detected require further testing by DNA sequencing. The LC480 and LightScanner platforms performed similarly.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.